Abstract
Several approved therapies for multicentric Castleman disease (MCD) cannot be uniformly applied due to intolerable side effects. There is also a high percentage of recurrence of this disease despite treatment. Rituximab may be effective in controlling MCD in a subset of patients. This paper includes a brief case report and an extensive review of previously published cases. We observed an aggravation of concomitant cutaneous Kaposi sarcoma, and hypothesize that rituximab could have exacerbated it.
This is a preview of subscription content, log in via an institution to check access.
References
Oksenhendler E, Duarte M, Soulier J et al (1996) Multicentric CD in HIV infection: a clinical and pathological study of 20 patients. AIDS 10:61
Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard JP (2002) Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis 35:880–882
Du MQ, Liu H, Diss TC et al (2001) Kaposi sarcoma-associated herpesvirus infects monotypic (IgMlambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97:2130
Marcelin AG, Aaron L, Mateus C et al (2003) Rituximab therapy for HIV-associated Castleman disease. Blood 102:2786
Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH (2003) A case of multicentric Castleman’s disease associated with advanced systemic amyloidosis treated with chemotherapy and anti CD-20 monoclonal antibody. Ann Hematol 82:766–768
Kofteridis DP, Tzagarakis N, Mixaki I, Maganas E, Xilouri E, Stathopoulos EN, Eliopoilos GD, Gikas A (2004) Multicentric Castleman’s disease: prolonged remission with anti CD-20 monoclonal antibody in an HIV-infected patients. AIDS 18(3):585–586
Marrache F, Larroche C, Memain N, Bouchoud O, Robineau M, Hermone O, Lortholary O (2003) Prolonged remission of HIV-associated multicentric Castleman’s disease with anti-CD20 monoclonal antibody as primary therapy. AIDS 17:1409–1410
Corbellino M, Bestetti G, Scalamogna C, Calattini S, Galazzi M, Meroni L, Manganaro D, Fasan M, Moroni M, Galli M, Parravicini C (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 98:3473–3475
Newsom-Davis T, Bower M, Wildfire A, Thirlwell C, Nelson M, Gazzard B, Stebbing J (2004) Resolution of AIDS-related Castleman’s disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels. Leuk Lymphoma 45(9):1939–1941
Ide M, Ogawa E, Kasagi K, Kawachi Y, Ogino T (2003) Successful treatment of multicentric Castleman’s disease with bilateral orbital tumour using rituximab. Br J Haematol 121:818
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Casquero, A., Barroso, A., Fernández Guerrero, M.L. et al. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. Ann Hematol 85, 185–187 (2006). https://doi.org/10.1007/s00277-005-0038-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-005-0038-4